Annexin A1: Potential for glucocorticoid sparing in RA

Nature Reviews Rheumatology

Volumn 9, Issue 10, 2013, Pages 595-603

  Yang, Yuan H ^a   Morand, Eric ^a   Leech, Michelle ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 6; LIPOCORTIN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; METHYLPREDNISOLONE; PYRAZOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL INTERACTION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADAPTIVE IMMUNITY; ANNEXIN A1; ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84885323803     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.126     Document Type: Review

References (88)

1. Seldin, M. F., Amos, C. I., Ward, R. & Gregersen, P. K. The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum. 42, 1071-1079 (1999). (Pubitemid 29268942)
2. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
3. Huscher, D. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 68, 1119-1124 (2009).
4. Kremer, J. M. et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58, 953-963 (2008). (Pubitemid 351563996)
5. Hoes, J. N., Jacobs, J. W., Verstappen, S. M., Bijlsma, J. W. & Van der Heijden, G. J. Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis. 68, 1833-1838 (2009).
6. Baschant, U., Lane, N. E. & Tuckermann, J. The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat. Rev. Rheumatol. 8, 645-655 (2012).
7. Flower, R. J. & Blackwell, G. J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 278, 456-459 (1979). (Pubitemid 9130706)
8. Wallner, B. P. et al. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 320, 77-81 (1986). (Pubitemid 16105252)
9. Perretti, M. & D'Acquisto, F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62-70 (2009).
10. Damazo, A. S. et al. Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation. Am. J. Pathol. 166, 1607-1617 (2005). (Pubitemid 40734384)
11. Yang, Y. H., Aeberli, D., Dacumos, A., Xue, J. R. & Morand, E. F. Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J. Immunol. 183, 1435-1445 (2009).
12. Zhang, Z., Huang, L., Zhao, W. & Rigas, B. Annexin 1 induced by anti-inflammatory drugs binds to NF-B and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res. 70, 2379-2388 (2010).
13. Yang, Y. H. et al. Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-dependent inflammation. J. Immunol. 190, 997-1007 (2013).
14. Walther, A., Riehemann, K. & Gerke, V. A novel ligand of the formyl peptide receptor: annexin 1 regulates neutrophil extravasation by interacting with the FPR. Mol. Cell 5, 831-840 (2000).
15. Perretti, M. et al. Endogenous lipid-and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296-1302 (2002). (Pubitemid 35373563)
16. Dufton, N. et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. 184, 2611-2619 (2010).
17. Buttgereit, F., Straub, R. H., Wehling, M. & Burmester, G. R. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 50, 3408-3417 (2004). (Pubitemid 39488664)
18. Fan, H. & Morand, E. F. Targeting the side effects of steroid therapy in autoimmune diseases: the role of GILZ. Discov. Med. 13, 123-133 (2012).
19. Weinstein, R. S. Glucocorticoid-induced osteonecrosis. Endocrine 41, 183-190 (2012).
20. Surjit, M. et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145, 224-241 (2011).
21. Patel, H. B. et al. The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann. Rheum. Dis. 71, 1872-1880 (2012).
22. Yang, Y. H. et al. Modulation of inflammation and response to dexamethasone by annexin 1 in antigen-induced arthritis. Arthritis Rheum. 50, 976-984 (2004). (Pubitemid 38326199)
23. Gerke, V. & Moss, S. E. Annexins and membrane dynamics. Biochim. Biophys. Acta 1357, 129-154 (1997). (Pubitemid 27278039)
24. Perretti, M. & Dalli, J. Exploiting the annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br. J. Pharmacol. 158, 936-946 (2009).
25. Lim, L. H. & Pervaiz, S. Annexin 1: the new face of an old molecule. FASEB J. 21, 968-975 (2007). (Pubitemid 46495688)
26. Croxtall, J. D. et al. Attenuation of glucocorticoid functions in an Anx-A1-/-cell line. Biochem. J. 371, 927-935 (2003). (Pubitemid 36578891)
27. Violette, S. M. et al. Role of lipocortin I in the glucocorticoid induction of the terminal differentiation of a human squamous carcinoma. J. Cell. Physiol. 142, 70-77 (1990).
28. Gerke, V. & Moss, S. E. Annexins: from structure to function. Physiol. Rev. 82, 331-371 (2002). (Pubitemid 34654456)
29. Blackwell, G. J. et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 287, 147-149 (1980). (Pubitemid 11227686)
30. Hannon, R. et al. Aberrant inflammation and resistance to glucocorticoids in annexin 1-/-mouse. FASEB J. 17, 253-255 (2003).
31. Babbin, B. A. et al. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J. Immunol. 181, 5035-5044 (2008).
32. Solito, E. et al. A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J 17, 1544-1546 (2003).
33. Scannell, M. et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J. Immunol. 178, 4595-4605 (2007). (Pubitemid 46492412)
34. Hayhoe, R. P. et al. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 107, 2123-2130 (2006). (Pubitemid 43289398)
35. Dalli, J. et al. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood 112, 2512-2519 (2008).
36. Perretti, M. et al. Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat. Med. 2, 1259-1262 (1996). (Pubitemid 26375414)
37. Brancaleone, V. et al. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J. Immunol. 186, 4905-4914 (2011).
38. Goulding, N. J. et al. Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone. Lancet 335, 1416-1418 (1990). (Pubitemid 20186434)
39. Morand, E. F. et al. Detection of intracellular lipocortin 1 in human leukocyte subsets. Clin. Immunol. Immunopathol. 76, 195-202 (1995).
40. Perretti, M. & Flower, R. J. Measurement of lipocortin 1 levels in murine peripheral blood leukocytes by flow cytometry: modulation by glucocorticoids and inflammation. Br. J. Pharmacol. 118, 605-610 (1996). (Pubitemid 26180973)
41. Spurr, L. et al. Comparative analysis of annexin A1-formyl peptide receptor 2/ALX expression in human leukocyte subsets. Int. Immunopharmacol. 11, 55-66 (2011).
42. Paschalidis, N. et al. Modulation of experimental autoimmune encephalomyelitis by endogenous annexin A1. J. Neuroinflammation 6, 33 (2009).
43. D'Acquisto, F. et al. Annexin-1 modulates T-cell activation and differentiation. Blood 109, 1095-1102 (2007). (Pubitemid 46220656)
44. D'Acquisto, F. et al. Impaired T cell activation and increased TH2 lineage commitment in Annexin-1-deficient T cells. Eur. J. Immunol. 37, 3131-3142 (2007). (Pubitemid 350131292)
45. Blume, K. E. et al. Cleavage of annexin A1 by ADAM10 during secondary necrosis generates a monocytic "find-me" signal. J. Immunol. 188, 135-145 (2012).
46. Hirata, F. & Iwata, M. Role of lipomodulin, a phospholipase inhibitory protein, in immunoregulation by thymocytes. J. Immunol. 130, 1930-1936 (1983). (Pubitemid 13091660)
47. Kamal, A. M., Smith, S. F., De Silva Wijayasinghe, M., Solito, E. & Corrigan, C. J. An annexin 1 (ANXA1)-derived peptide inhibits prototype antigen-driven human T cell TH1 and TH2 responses in vitro. Clin. Exp. Allergy 31, 1116-1125 (2001). (Pubitemid 32862843)
48. Gold, R., Pepinsky, R. B., Zettl, U. K., Toyka, K. V. & Hartung, H. P. Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat. J. Neuroimmunol. 69, 157-164 (1996).
49. Ng, F. S. et al. Annexin-1-deficient mice exhibit spontaneous airway hyperresponsiveness and exacerbated allergen-specific antibody responses in a mouse model of asthma. Clin. Exp. Allergy 41, 1793-1803 (2011).
50. Yang, Y., Hutchinson, P. & Morand, E. F. Inhibitory effect of annexin 1 on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum. 42, 1538-1544 (1999). (Pubitemid 30265613)
51. Yang, Y., Leech, M., Hutchinson, P., Holdsworth, S. R. & Morand, E. F. Antiinflammatory effect of lipocortin 1 in experimental arthritis. Inflammation 21, 583-596 (1997). (Pubitemid 28026329)
52. Korganow, A. S. et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10, 451-461 (1999).
53. Bevaart, L., Vervoordeldonk, M. J. & Tak, P. P. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis Arthritis Rheum. 62, 2192-2205 (2010).
54. van den Berg, W. B. Lessons from animal models of arthritis over the past decade. Arthritis Res. Ther. 11, 250 (2009).
55. Baschant, U. et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc. Natl Acad. Sci. USA 108, 19317-19322 (2011).
56. Morand, E. F., Jefferiss, C. M., Dixey, J., Mitra, D. & Goulding, N. J. Impaired glucocorticoid induction of mononuclear leukocyte lipocortin-1 in rheumatoid arthritis. Arthritis Rheum. 37, 207-211 (1994). (Pubitemid 24065495)
57. Goulding, N. J., Jefferiss, C. M., Pan, L., Rigby, W. F. & Guyre, P. M. Specific binding of lipocortin-1 (annexin I) to monocytes and neutrophils is decreased in rheumatoid arthritis. Arthritis Rheum. 35, 1395-1397 (1992).
58. Sampey, A. V., Hutchinson, P. & Morand, E. F. Annexin I surface binding sites and their regulation on human fibroblast-like synoviocytes. Arthritis Rheum. 43, 2537-2542 (2000).
59. D'Acquisto, F. et al. Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells. Rheumatology (Oxford) 47, 636-639 (2008). (Pubitemid 351619203)
60. Goulding, N. J. et al. Differential distribution of annexins-I,-II,-IV, and-VI in synovium. Ann. Rheum. Dis. 54, 841-845 (1995).
61. Morand, E. F., Hall, P., Hutchinson, P. & Yang, Y. H. Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm. 2006, 73835 (2006).
62. Tagoe, C. E. et al. Annexin-1 mediates TNF--stimulated matrix metalloproteinase secretion from rheumatoid arthritis synovial fibroblasts. J. Immunol. 181, 2813-2820 (2008).
63. Ye, R. D. et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61, 119-161 (2009).
64. Gavins, F. N. & Hickey, M. J. Annexin A1 and the regulation of innate and adaptive immunity. Front. Immunol. 3, 354 (2012).
65. Fiore, S., Maddox, J. F., Perez, H. D. & Serhan, C. N. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180, 253-260 (1994). (Pubitemid 24181074)
66. Su, S. B. et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189, 395-402 (1999). (Pubitemid 29063260)
67. Hartt, J. K., Barish, G., Murphy, P. M. & Gao, J. L. N-formylpeptides induce two distinct concentration optima for mouse neutrophil chemotaxis by differential interaction with two N-formylpeptide receptor (FPR) subtypes. Molecular characterization of FPR2, a second mouse neutrophil FPR. J. Exp. Med. 190, 741-747 (1999). (Pubitemid 29428656)
68. Chiang, N. et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58, 463-487 (2006). (Pubitemid 44394909)
69. Maderna, P. et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J. 24, 4240-4249 (2010).
70. Jia, Y. et al. Regulation of lung fibroblast activation by annexin A1. J. Cell. Physiol. 228, 476-484 (2013).
71. Bena, S., Brancaleone, V., Wang, J. M., Perretti, M. & Flower, R. J. Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J. Biol. Chem. 287, 24690-24697 (2012).
72. Perretti, M. & Flower, R. J. Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1. J. Immunol. 150, 992-999 (1993). (Pubitemid 23133679)
73. Perretti, M., Ahluwalia, A., Harris, J. G., Goulding, N. J. & Flower, R. J. Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J. Immunol. 151, 4306-4314 (1993). (Pubitemid 23298764)
74. Tae, Y. M. et al. Airway activation of formyl peptide receptors inhibits TH1 and TH17 cell responses via inhibition of mediator release from immune and inflammatory cells and maturation of dendritic cells. J. Immunol. 188, 1799-1808 (2012).
75. Sogawa, Y., Shimizugawa, A., Ohyama, T., Maeda, H. & Hirahara, K. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist. J. Pharmacol. Sci. 111, 317-321 (2009).
76. Burli, R. W. et al. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett. 16, 3713-3718 (2006). (Pubitemid 44137222)
77. Kirpotina, L. N. et al. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol. Pharmacol. 77, 159-170 (2010).
78. Schepetkin, I. A., Kirpotina, L. N., Khlebnikov, A. I., Jutila, M. A. & Quinn, M. T. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors. Mol. Pharmacol. 79, 77-90 (2011).
79. Damazo, A. S., Yona, S., Flower, R. J., Perretti, M. & Oliani, S. M. Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J. Immunol. 176, 4410-4418 (2006). (Pubitemid 44264421)
80. Gavins, F. N., Dalli, J., Flower, R. J., Granger, D. N. & Perretti, M. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation. FASEB J. 21, 1751-1758 (2007). (Pubitemid 46855621)
81. Damazo, A. S. et al. Endogenous annexin A1 counter-regulates bleomycin-induced lung fibrosis. BMC Immunol. 12, 59 (2011).
82. Qin, C. et al. Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-A1 and its N-terminal-derived peptide Ac-ANX-A1(2-26). Br. J. Pharmacol. 168, 238-252 (2013).
83. Cristante, E. et al. Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. Proc. Natl Acad. Sci. USA 110, 832-841 (2013).
84. Lee, S. H. et al. Anti-inflammatory effects of Tat-annexin protein on ovalbumin-induced airway inflammation in a mouse model of asthma. Biochem. Biophys. Res. Commun. 417, 1024-1029 (2012).
85. Vago, J. P. et al. Annexin A1 modulates natural and glucocorticoid- induced resolution of inflammation by enhancing neutrophil apoptosis. J. Leukoc. Biol. 92, 249-258 (2012).
86. da Cunha, E. E., Oliani, S. M. & Damazo, A. S. Effect of annexin-A1 peptide treatment during lung inflammation induced by lipopolysaccharide. Pulm. Pharmacol. Ther. 25, 303-311 (2012).
87. Kamaly, N. et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl Acad. Sci. USA 110, 6506-6511 (2013).
88. Leoni, G. et al. Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J. Clin. Invest. 123, 443-454 (2013).